Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Academic Article uri icon

Overview

abstract

  • BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. RESULTS: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m(2), and duration of T2DM was 9.3 ± 8.2 years. The qualifying ACS was a myocardial infarction in 83% and unstable angina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. CONCLUSION: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk.

authors

  • Malik, Rayaz A.
  • Bentley-Lewis, Rhonda
  • Aguilar, David
  • Riddle, Matthew C
  • Claggett, Brian
  • Diaz, Rafael
  • Dickstein, Kenneth
  • Gerstein, Hertzel C
  • Johnston, Peter
  • Køber, Lars V
  • Lawson, Francesca
  • Lewis, Eldrin F
  • Maggioni, Aldo P
  • McMurray, John J V
  • Ping, Lin
  • Probstfield, Jeffrey L
  • Solomon, Scott D
  • Tardif, Jean-Claude
  • Wu, Yujun
  • Pfeffer, Marc A

publication date

  • February 12, 2015

Research

keywords

  • Acute Coronary Syndrome
  • Peptides
  • Protein Kinase Inhibitors
  • p38 Mitogen-Activated Protein Kinases

Identity

Scopus Document Identifier

  • 84929289581

Digital Object Identifier (DOI)

  • 10.1016/j.ahj.2015.02.002

PubMed ID

  • 25965710

Additional Document Info

volume

  • 169

issue

  • 5